(Q42492321)

English

Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

0 references

author name string

L Baggio

1

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

F Adatia

2

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

T Bock

3

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

P L Brubaker

4

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

D J Drucker

5

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

language of work or name

0 references

publication date

1 November 2000

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Journal of Biological Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

275

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

34471-34477

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Bioactive peptides from lizard venoms

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian h

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Tissue-specific posttranslational processing of pre-prosomatostatin encoded by a metallothionein-somatostatin fusion gene in transgenic mice.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Role of prohormone convertases in the tissue-specific processing of proglucagon

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Metallothionein-Human GH Fusion Genes Stimulate Growth of Mice

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

The human growth hormone gene family: nucleotide sequences show recent divergence and predict a new polypeptide hormone

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

A role for glucagon-like peptide-1 in the central regulation of feeding

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Normoglycemia Restores -Cell Replicative Response to Glucose in Transplanted Islets Exposed to Chronic Hyperglycemia

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Glucagon-like peptide-I-(7-37) suppresses hyperglycemia in rats.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

The glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Homologous Desensitization of the Insulinotropic Glucagon-Like Peptide-I(7–37) Receptor on Insulinoma (HIT-T15) Cells*

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Desensitization of glucagon-like peptide 1 receptors in insulin-secreting beta TC3 cells: role of PKA-independent mechanisms

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP- 1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Exendin-4 and exendin-(9–39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH2

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M005119200

21 January 2018

Identifiers

10.1074/JBC.M005119200

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42492321&oldid=1959600671"